IHS Chemical Week

Regions :: North America :: U.S.

Lonza signs manufacturing deal with US biotech firm

12:08 AM MDT | October 2, 2012 | Deepti Ramesh

Lonza says it has entered into a process transfer and manufacturing agreement with Celladon Corp. (San Diego, CA), a privately held biotechnology company focused on the discovery and development of treatments for cardiovascular diseases. Lonza, under the terms of the agreement, will manufacture cGMP-grade Mydicar, Celladon’s product candidate for the treatment of advanced heart failure, for use in future clinical trials. In the event Celladon intends to commence commercial scale manufacture of Mydicar, Celladon and Lonza have agreed to negotiate a...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa